Literature DB >> 8364348

Time course of improvement under antidepressant treatment: a survival-analytical approach.

H H Stassen1, A Delini-Stula, J Angst.   

Abstract

A meta-analysis of an earlier multicenter, double-blind efficacy study comparing placebo, oxaprotiline and amitriptyline was performed in order to test the survival-analytical approach in modelling the onset of improvement and response to treatment with antidepressants. The sample consisted of moderately depressed male (n = 154) and female (n = 275) patients (aged 17-73), diagnosed according to DSM-III criteria for major depression. Of these, 120 were treated with oxaprotiline, 120 with amitriptyline and 189 with placebo. Efficacy criteria were Hamilton Depression (HAMD) and Anxiety (HAMA) and Zung Self-Rating scales. Up to eight ratings over a period of 40 days were available for analysis. The results showed that the sensitivity in discriminating between groups was substantially enhanced through the inclusion of drop-outs and consideration of the effect of time to withdrawal from the study due to lack of improvement. Withdrawal from the trial due to inefficacy occurred earliest under placebo (50% within the first 8 days), whereas less than 40% dropped out within the first 12 days under active treatments. The most interesting and unexpected finding of the analysis was that the time course of improvement among responders was independent of the treatment modality, and thus identical in all three groups. Specifically, the efficacy of any of the given treatments was reflected only by the total number of responders or nonresponders. Once triggered, the time course of recovery from illness becomes identical to that of spontaneous remissions as observed, for example, under placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364348     DOI: 10.1016/0924-977x(93)90264-m

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  28 in total

Review 1.  Improvement of depression following transcranial magnetic stimulation.

Authors:  M S George; Z Nahas; F A Kozel; J Goldman; M Molloy; N Oliver
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

3.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

4.  Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.

Authors:  David E Kemp; Stephen J Ganocy; Martin Brecher; Berit X Carlson; Suzanne Edwards; James M Eudicone; Gary Evoniuk; Wim Jansen; Andrew C Leon; Margaret Minkwitz; Andrei Pikalov; Hans H Stassen; Armin Szegedi; Mauricio Tohen; Arjen P P Van Willigenburg; Joseph R Calabrese
Journal:  J Affect Disord       Date:  2010-11-10       Impact factor: 4.839

5.  Patterns of depressive symptom remission during the treatment of seasonal affective disorder with cognitive-behavioral therapy or light therapy.

Authors:  Jonah Meyerhoff; Michael A Young; Kelly J Rohan
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

Review 6.  Prospects for the development of new treatments with a rapid onset of action in affective disorders.

Authors:  J C Soares; S Gershon
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

7.  High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.

Authors:  Thorsten Mikoteit; Johannes Beck; Anne Eckert; Ulrich Hemmeter; Serge Brand; Roland Bischof; Edith Holsboer-Trachsler; Alexandra Delini-Stula
Journal:  Psychopharmacology (Berl)       Date:  2014-02-23       Impact factor: 4.530

8.  Early improvement with lithium in classic mania and its association with later response.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Marcio G Soeiro-de-Souza; Getulio Marca; Ioline D Henter; Joao V Busnello; Wagner F Gattaz; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-17       Impact factor: 4.839

9.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

10.  Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy.

Authors:  Sunil S Bhar; Lois A Gelfand; Sabine P Schmid; Robert Gallop; Robert J DeRubeis; Steven D Hollon; Jay D Amsterdam; Richard C Shelton; Aaron T Beck
Journal:  J Affect Disord       Date:  2008-02-13       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.